85results about How to "Control blood sugar levels" patented technology

The invention discloses exendin-4, an analog fusion protein thereof, the corresponding polynucleotide sequence, carrier, host cell and pharmaceutical composite and a preparation method and applications of the fusion protein. The fusion protein is prepared by fusing exendin-4 and analog thereof with human immunoglobulin IgG2-Fc through special connecting peptide and has better stability and loner half-life in vivo. The fusion protein can be administered by performing local delivery, using aerosol and using injection. The fusion protein can promote the regeneration and repair of islet beta cells, increase islet beta cells, promote the secretion of insulin and improve the sensitivity of organism to insulin. The fusion protein is used to cure diabetes, adiposity and other diseases which can be benefited by reducing plasma glucose and inhibiting gastrointestinal motility and gastric emptying.

The invention discloses a medicinal composition for treating diabetes. The medicinal composition consists of astragalus, gardenia, Szechuan lovage rhizome, siberian solomonseal rhizome, finger citron, root of red-rooted salvia, cinnamomvine, swordlike atractylodes rhizome, white paeony root, perilla fruit, kudzuvine root, fragrant solomonseal rhizome, oyster shell, rehmannia root, Chinese angelica, common anemarrhena rhizome, honeysuckle flower, heartleaf houttuynia herb, fresh imperata root, Chinese caterpillar fungus, semen nelumbinis, siberian solomonseal rhizome, cornus fruit, prepared rehmannia root, villous amomum fruit, liquoric root, medlar, asparagus, black sesame, tuckahoe, cherokee rose fruit, cistanche deserticola, angelica dahurica, adenophora, dark plum fruit, complanate astragalus seed, cassia seed, mulberry leaf, fresh reed rhizome, mint, oriental waterplantain rhizome, wrinkled gianthyssop herb and parslane herb. The medicinal composition can control the blood sugar level of various patients who suffer from the diabetes and improve the clinical symptoms of diabetes complications effectively. Therefore the medicinal composition can be used for treating the diabetesand the diabetes complications such as diabetic gastroparesis, diabetic nephroma, diabetic foot, diabetic neuropathy, diabetic eye diseases and diabetic pruritus and the like.

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and / or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

The present invention relates to a herbal health protective, promotive and disease preventive nutraceutical herbal formulation(s) for diabetics, and also relates to a process for the preparation of a herbal health protective, promotive and disease preventive nutraceutical herbal formulation as food supplement to ameliorate the general health of diabetics, said formulation comprises the base product of microwave roasted seed powders mixture from selected genera of Glycine, Cicer, Phaseolus, Cyamompsis, Mucuna, Hordeum, Amaranthus and Fagopyrum, fortified with herbs / medicinal plants used are selected from the genera of Gymnema, Momordica, Syzgium, Pterocarpus, Trigonella, Cinnamomum, Withania, Coccinia, Pueraria, Asparagus, Boerhaavia and Aegle and also some other ingredients like Piper longum, Chlorophytum tuberosum, Curcuma longa and Elettaria cardamomum were also added to get the final nutraceutical product(s); the nutraceuticals are with optimum nutrition, non toxic, natural herbal plant products, easy to digest, have health protective and promotive properties to ameliorate the general health and vigor of diabetics.

The invention relates to the technical field of biology, and particularly, relates to a recombinant human GLP-1-Fc fusion protein and a preparation method and an application thereof. The invention provides the recombinant human GLP-1-Fc fusion protein, wherein the recombinant human GLP-1-Fc fusion protein comprises two structural function regions which are respectively a recombinant GLP-1 fragment and a human immunoglobulin Fc fragment, and the recombinant GLP-1 fragment has the amino acid sequence shown in SEQID No.1. The recombinant human GLP-1-Fc fusion protein provided by the invention has the homology with an original GLP-1 molecule reaching 97%, and still maintains excellent biological activity and zoology activity.

An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and / or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-α-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well. The present compositions are useful for amelioration of cholesterolemia, obesity, chronic complications of diabetes and prophylaxis for patients predisposed to the foregoing.

The invention discloses hyperglycosylated Extendin-4, fusion protein of analogue thereof, and a preparation method and the application of fusion protein. The fusion protein comprises Extendin-4, the analogue of the Extendin-4, a flexible peptide joint, at least one human chorionic gonadotropin beta carboxyl terminal peptide rigid unit and a human immunoglobulin Fc fragment. The invention also discloses the preparation method and the application of the fusion protein. The fusion protein has optimal biological activity, obviously prolonged circulation half-time, lowered immunogenicity and improved bioavailability. The fusion protein can be used for treating diabetes, obesity and other diseases benefited by lowering fasting plasma glucose, inhibiting stomach and / or bowel movement and inhibiting and / or bowel evacuation or inhibiting food intake.

The invention relates to the technical field of medicines for treating diabetes, in particular to a fusion protein for treating diabetes and a preparation method for the fusion protein. The fusion protein is recombined by 2 to 8 Exendin-4-Linkers and a human IgGFc mutant; Linker is a flexible peptide fragment; and the human IgGFc mutant is an IgG1Fc, IgG2Fc or IgG4Fc mutant. The invention also discloses the preparation method for the fusion protein. The recombined fusion protein obtained by the steps of performing high-level expression in Chinese hamster ovary (CHO) cells, affiliating, and performing ion exchange and molecular sieve chromatography has the bioactivities of stimulating the secretion of insulin and inhibiting glucagon generated after dinner from being released which are possessed by Exendin-4, also has the characteristics of prolonging the half-life period of the Exendin-4 in serum, is used for treating type I and type II diabetes, can effectively reduce the psychological and physiological burden of patients, is safe in use and high in practicability, and can be massively produced and sold.

The invention relates to a diabetes treatment composition based on traditional Chinese medicine nutritional therapy and application thereof, wherein the diabetes treatment composition mainly comprisesvarious natural materials including medicinal and edible materials. The diabetes treatment composition is a low-GI composition, comprising various compound ingredients which may present through carbohydrates, fats and dietary fiber; by usage each day, the dietary fiber in the composition accounts for 10-40 g; the diabetes treatment composition has the total energy of 400-1300 calories, wherein energy provided according to the present quantity of carbohydrates is 15-45% of the total energy of the composition herein; energy provided according to the present quantity of fat is 40-80% of the total energy of the composition, wherein the mass of unsaturated fatty acids is 50-80% of total mass of fat. The composition provided herein lays emphasis on the here-low three-high structure of low GI, low calorie, low available carbohydrates, high unsaturated fatty acids, high dietary fiber and high homology of medicine and food; the intermittent fasting means helps reduce the glucose level of a diabetic patient effectively.

The invention relates to a chitosan oligosaccharide composite powder with adjuvant hpyerglycemic function. The chitosan oligosaccharide composite powder comprises, by weight, 40 to 60 parts of oat beta-glucan, 5 to 20 parts of chitosan oligosaccharide, 5 to 20 parts of sealwort extract, 3 to 8 parts of mulberry leaf extract, 2 to 6 parts of balsam pear extract, 0.05 to 0.5 part of chromium-rich yeast and 10 to 20 parts of a filler. The invention has the following advantages: the chitosan oligosaccharide composite powder is a chitosan oligosaccharide compound prepared from chitosan oligosaccharide and oat beta-glucan, used as main effective components, and a plurality of traditional Chinese medicinal active components, used as adjuvant materials, through refining in virtue of ultrasonic emulsification and spray drying technologies; the chitosan oligosaccharide composite powder has the advantages of good dissolvability, good dispersibility and high absorption and availability; all the components of the chitosan oligosaccharide composite powder cooperate with each other to exert substantial effect on promotion of blood glucose metabolism and maintenance and adjustment of the functions of the pancreas islet; moreover, a variety of active components included in the chitosan oligosaccharide composite powder has obvious synergism in improving the sensitivity of insulin and stabilizing postprandial blood sugar.

The invention discloses a weighing analyzing apparatus, comprising a weighing device, a storage device, input / output (I / O) equipment, a component analysis module and a guide module, wherein, the weighing device is used for transmitting a measuring result to the component analysis module; the component analysis module is used for inquiring component information of an object from an object componenttable of the storage device according to an object identification input by the I / O equipment, and calculating the component content of the weighed object according to the measuring weight result; andthe guide module is used for determining a guidance suggestion according to the component content and a preset guide program, and sending the suggestion to the I / O equipment for output. The inventionfurther discloses a weighing analysis method. The invention can realize automatic weighing and calculating, and simply and accurately obtain the guidance suggestion related to object weight.

The invention discloses a generalized predictive control closed-loop insulin infusion system based on an adaptive reference curve strategy. The system comprises a blood glucose detection module, a controller, a program module and an insulin pump, the blood glucose detection module is used for acquiring the blood glucose of a user, and an output end of the blood glucose detection module is connected with an input end of the controller through signals. The insulin pump is used for infusing insulin into the user, and an input end of the insulin pump is connected with an output end of the controller through signals. The program module is executed by the controller, acquires the blood glucose of the user through the blood glucose detection module and adjusts the infusion rate of the insulin pump according to a CARIMA (controlled autoregressive integral moving average) model, a minimum variance control algorithm and the adaptive reference curve strategy. According to the generalized predictive control closed-loop insulin infusion system based on the adaptive reference curve strategy, adaptive reference curves can be generated according to blood glucose fluctuation of different patients,so that the infusion rate of the insulin pump can be flexibly controlled.

The present invention provides a composition for treating and / or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type I diabetes protein antigenic epitope polypeptide and an immunosuppressor, 3.) a mixture of a type I diabetes protein antigen, a type I diabetes protein antigenic epitope polypeptide, and an immunosuppressor; the type I diabetes protein antigen is at least one of insulin, glutamic acid decarboxylase, and islet amyloid polypeptide, and the immunosuppressor is at least one of dexamethasone, cyclosporine A, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, early prednisolone, anti-CD4 monoclonal antibody, and anti-CD3 monoclonal antibody.

The invention discloses an inulin low-fat yogurt pudding and a preparation method thereof, and belongs to the technical field of food processing. The inulin low-fat yogurt pudding is prepared from the following components by weight percent: 30-40% of yogurt base, 2-10% of inulin, 0.05-0.5% of a thickener, 0.001-5% of a sweetening agent and the balance of water, wherein the inulin is a soluble dietary fiber, can selectively promote growth of colon probiotics, and has the functions of reducing blood sugar concentration, maintaining lipid metabolism balance, improving the bioavailability of mineral elements, enhancing the immunity of the organism, and the like. The inulin low-fat yogurt pudding disclosed by the invention contains the inulin dietary fiber, is low in fat content, and smooth in mouthfeel, has the functions of improving the intestinal microenvironment, controlling blood fat and blood sugar levels, reducing the energy, promoting absorption of a mineral substance and synthesis of vitamins, and is especially suitable for middle aged and elderly people with diseases such as constipation, obesity, hypertension, hyperlipidemia and diabetes mellitus.

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

The invention discloses a pharmaceutical composition for treating or preventing diabetes or its complications and an application thereof, and belongs to the medical field. According to the pharmaceutical composition, an insulin sensitizer and bromocriptine or its medicinal salt are used as active pharmaceutical ingredients. When the pharmaceutical composition is used to treat or prevent diabetes or its complications, the medical action modes are complementary. Therefore, the pharmaceutical composition shows remarkable synergism in the hypoglycemic aspect, has low adverse reaction, requires a low price and has a good application prospect.

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of RYZN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

The invention discloses an insulin infusion controlling device. The method comprises the following steps of: firstly, receiving infusion time length and infusion total amount input by a user, presetting infusion time intervals, and dividing the infusion time length according to the infusion time intervals to obtain infusion time period number; when the infusion time period number is larger than or equal to 2, calculating to obtain infusion base number according to the infusion time period number and the infusion total amount, and calculating to obtain infusion amount of each infusion time period; and finally, carrying out infusion according to the calculated infusion amount. The infusion amount in each time period obtained through the infusion controlling method is sequentially increased, so that the eating habits of drinking first, eating high protein diet and then eating high-calorie food of Chinese people attending a party are met, the content of insulin in a human body is matched with the level of sugar absorbing from food, and further the blood glucose level in the body of a patient can be more effectively controlled.

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and / or trehalulose in the carbohydrate energy percentage is 60 to 100%.The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

The invention discloses an Exendin-4 analogue fused with a human IgG2 Fc variation and a preparation method of the Exendin-4 analogue. The circulating half-life period of the fusion protein is remarkably prolonged, and the biological availability is greatly improved. The fusion protein can be used for treating diabetes, obesity and other diseases that are benefited by lowering plasma glucose, inhibiting gastric and / or intestinal motion and inhibiting gastric and / or intestinal emptying or inhibiting food intake.

The invention discloses hyperglycosylated Extendin-4, fusion protein of analogue thereof, and a preparation method and the application of fusion protein. The fusion protein comprises Extendin-4, the analogue of the Extendin-4, a flexible peptide joint, at least one human chorionic gonadotropin beta carboxyl terminal peptide rigid unit and a human immunoglobulin Fc fragment. The invention also discloses the preparation method and the application of the fusion protein. The fusion protein has optimal biological activity, obviously prolonged circulation half-time, lowered immunogenicity and improved bioavailability. The fusion protein can be used for treating diabetes, obesity and other diseases benefited by lowering fasting plasma glucose, inhibiting stomach and / or bowel movement and inhibiting and / or bowel evacuation or inhibiting food intake.

The invention discloses a beta-amino ketones compound with anti-diabetic activity, particularly the compound which has the general formula (I) as shown on the right or a pharmaceutically acceptable salt thereof. The invention can increase insulin sensitivity and / or decrease postprandial blood glucose level, and prevent and delay the outbreak and the development of diabetes mellitus and complications thereof, has simple preparation method, low cost and good potential application value and can be prepared to be anti-diabetic medicine for preventing and treating the diabetes mellitus.

The invention discloses hair blackening, beauty maintaining and young keeping medicinal food applicable to diabetes patients. The medicinal food comprises the following raw materials: in parts by weight, 500-1500 parts of yak tripe, 80-100 parts of valerian root powder, 80-100 parts of grape seeds, 80-100 parts of donkey-hide gelatin, 40-60 parts of common yam rhizomes, 30-50 parts of black sesame, 6-18 parts of prepared fleece flower roots, 12-36 parts of rehmannia rhizomes, 6-18 parts of corn stigma and the like. The hair blackening, beauty maintaining and young keeping medicinal food disclosed by the invention takes the yak tripe, valerian roots, the grape seeds and the donkey-hide gelatin as the monarch, and is based on the traditional Chinese medicine composition principle and combined with the latest achievement of modern pharmacological studies, so that scientificity and reasonability of the compatibility of the medicine materials are guaranteed. The medicinal food can replenish qi, enrich the blood, promote circulation, remove stasis, enrich yin and nourish kidney, invigorate the spleen and benefit the stomach, is beneficial to organism immunity improvement, and recuperates the appearance from the inside, has special effects of blood glucose reduction, antioxidation, aging resistance, hair blackening, beauty maintaining, young keeping and female hormone level adjustment, and is particularly suitable for being eaten daily by adult female diabetes patients.

The invention provides an individualized intervention formula food for diabetes and a preparation system thereof. The individualized intervention formula food for the diabetes is prepared by the following steps: 1), determining diabetes-related gene polymorphism sites which are effective for nutrient intervention; 2), detecting mutation of individual ADIPOQ gene, SLC30A8 gene and IL-6 gene; 3), evaluating mutation risk of the detected genes; and 4), determining addition amounts of various ingredients in the individualized intervention formula food, and preparing a corresponding individualized intervention formula food by using a preparation unit of the individualized intervention formula food. The individualized intervention formula food for the diabetes provided by the invention is capable of effectively reducing blood glucose level of patients with the diabetes.

The invention discloses a preparing method for oral insulin transport system in layer-by-layer self-assembly structure comprising the steps of separating out insulin nano ball with electropositivity by salting out method under the condition of low pH, and successively packing the insulin nano ball using polygalacturonic acid (PGLA) with electronegativity and chitosan (CS) with electropositivity by layer-by-layer self-assembly method according to the electrical property and electrostatic force of materials. The oral insulin transport system in the invention is characterized by nature, low toxicity, natural metabolism and degradation and excellent biocompatibility, and has small partical size, strong small-intestine absorption rate, high drug loading ratio and excellent stability. The system can quickly and potently exert the hypoglycemic effect of insulin and also obviously and quickly control the blood glucose level in a long-term with the potential of diabetes treatment.

The invention belongs to the technical field of medicine, and specifically discloses a medicine for treating diabetes and its application. It consists of the following raw materials in terms of weight fraction: 5-10 parts of glibenclamide, 15-20 parts of ginkgo extract, and 5 parts of bromocriptine -10 parts, 10-15 parts of dextrin, 0.1-0.5 parts of malic acid, 1-5 parts of glycyrrhizin, 0.1-0.5 parts of magnesium stearate and 5-10 parts of microcrystalline cellulose. The medicine for treating diabetes of the present invention can effectively solve the problem that type 2 diabetes cannot be effectively controlled by taking common hypoglycemic medicine alone in the prior art, and has the effects of controlling blood sugar, synergistically protecting endothelial cell function, reducing diabetic complications and the like.